These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 30773266)
1. Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction. Suhrs HE; Raft KF; Bové K; Madsbad S; Holst JJ; Zander M; Prescott E Int J Cardiol; 2019 May; 283():28-34. PubMed ID: 30773266 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive treatment of microvascular angina in overweight women - a randomized controlled pilot trial. Bove KB; Nilsson M; Pedersen LR; Mikkelsen N; Suhrs HE; Astrup A; Prescott E PLoS One; 2020; 15(11):e0240722. PubMed ID: 33151955 [TBL] [Abstract][Full Text] [Related]
3. Coronary microvascular dysfunction and myocardial contractile reserve in women with angina and no obstructive coronary artery disease. Michelsen MM; Pena A; Mygind ND; Bech J; Gustafsson I; Kastrup J; Hansen HS; Høst N; Hansen PR; Prescott E Echocardiography; 2018 Feb; 35(2):196-203. PubMed ID: 29222822 [TBL] [Abstract][Full Text] [Related]
4. Peripheral Reactive Hyperemia Index and Coronary Microvascular Function in Women With no Obstructive CAD: The iPOWER Study. Michelsen MM; Mygind ND; Pena A; Aziz A; Frestad D; Høst N; Prescott E; JACC Cardiovasc Imaging; 2016 Apr; 9(4):411-7. PubMed ID: 27056160 [TBL] [Abstract][Full Text] [Related]
5. Peripheral Endothelial Function and Coronary Flow Velocity Reserve Are Not Associated in Women with Angina and No Obstructive Coronary Artery Disease: The iPOWER Study. Flintholm Raft K; Frestad D; Michelsen MM; Suhrs HE; Rask AB; Nilsson M; Hermann TS; Prescott E J Vasc Res; 2017; 54(5):309-319. PubMed ID: 28942444 [TBL] [Abstract][Full Text] [Related]
6. Coronary microvascular dysfunction is associated with cardiac time intervals in women with angina and no obstructive coronary artery disease: An iPOWER substudy. Pena A; Michelsen MM; Mygind ND; Gustafsson I; Høst N; Bech J; Kastrup J; Hansen HS; Hansen PR; Prescott E Echocardiography; 2019 Jun; 36(6):1110-1117. PubMed ID: 31012159 [TBL] [Abstract][Full Text] [Related]
7. Impaired coronary flow velocity reserve is associated with cardiovascular risk factors but not with angina symptoms. Bove KB; Michelsen MM; Schroder J; Suhrs HE; Bechsgaard DF; Mygind ND; Aziz A; Kastrup J; Gustafsson I; Prescott E Open Heart; 2021 Jan; 8(1):. PubMed ID: 33462108 [TBL] [Abstract][Full Text] [Related]
8. Coronary microvascular function and myocardial fibrosis in women with angina pectoris and no obstructive coronary artery disease: the iPOWER study. Mygind ND; Michelsen MM; Pena A; Qayyum AA; Frestad D; Christensen TE; Ghotbi AA; Dose N; Faber R; Vejlstrup N; Hasbak P; Kjaer A; Prescott E; Kastrup J; J Cardiovasc Magn Reson; 2016 Nov; 18(1):76. PubMed ID: 27809867 [TBL] [Abstract][Full Text] [Related]
9. Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study. Schroder J; Michelsen MM; Mygind ND; Suhrs HE; Bove KB; Bechsgaard DF; Aziz A; Gustafsson I; Kastrup J; Prescott E Eur Heart J; 2021 Jan; 42(3):228-239. PubMed ID: 33477168 [TBL] [Abstract][Full Text] [Related]
10. Effect of ACE-inhibition on coronary microvascular function and symptoms in normotensive women with microvascular angina: A randomized placebo-controlled trial. Michelsen MM; Rask AB; Suhrs E; Raft KF; Høst N; Prescott E PLoS One; 2018; 13(6):e0196962. PubMed ID: 29883497 [TBL] [Abstract][Full Text] [Related]
11. Myocardial CT perfusion compared with transthoracic Doppler echocardiography in evaluation of the coronary microvascular function: An iPOWER substudy. Bechsgaard DF; Hove JD; Michelsen MM; Mygind ND; Pena A; Hansen PR; Hansen HS; Kastrup J; Høst N; Gustafsson I; Prescott E Clin Physiol Funct Imaging; 2021 Jan; 41(1):85-94. PubMed ID: 33030280 [TBL] [Abstract][Full Text] [Related]
12. Coronary microvascular dysfunction is not associated with a history of reproductive risk factors in women with angina pectoris-An iPOWER substudy. Suhrs HE; Kristensen AM; Rask AB; Michelsen MM; Frestad D; Mygind ND; Bové K; Prescott E Maturitas; 2018 Jan; 107():110-115. PubMed ID: 28807722 [TBL] [Abstract][Full Text] [Related]
13. Coronary Microvascular Function and Cardiovascular Risk Factors in Women With Angina Pectoris and No Obstructive Coronary Artery Disease: The iPOWER Study. Mygind ND; Michelsen MM; Pena A; Frestad D; Dose N; Aziz A; Faber R; Høst N; Gustafsson I; Hansen PR; Hansen HS; Bairey Merz CN; Kastrup J; Prescott E J Am Heart Assoc; 2016 Mar; 5(3):e003064. PubMed ID: 27068634 [TBL] [Abstract][Full Text] [Related]
14. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study. Faber R; Zander M; Pena A; Michelsen MM; Mygind ND; Prescott E Cardiovasc Diabetol; 2015 Apr; 14():41. PubMed ID: 25896352 [TBL] [Abstract][Full Text] [Related]
15. Temporal Trends in Angina, Myocardial Perfusion, and Left Ventricular Remodeling in Women With No Obstructive Coronary Artery Disease Over 1-Year Follow-Up: Results From WISE-CVD. Quesada O; Hermel M; Suppogu N; Aldiwani H; Shufelt C; Mehta PK; Cook-Wiens G; Maughan J; Berman DS; Thomson LEJ; Handberg EM; Pepine CJ; Bairey Merz CN; Wei J J Am Heart Assoc; 2020 Jul; 9(13):e016305. PubMed ID: 32578481 [TBL] [Abstract][Full Text] [Related]
17. Transthoracic Doppler echocardiography compared with positron emission tomography for assessment of coronary microvascular dysfunction: The iPOWER study. Michelsen MM; Mygind ND; Pena A; Olsen RH; Christensen TE; Ghotbi AA; Hasbak P; Kjaer A; Gustafsson I; Hansen PR; Hansen HS; Høst N; Kastrup J; Prescott E Int J Cardiol; 2017 Feb; 228():435-443. PubMed ID: 27870973 [TBL] [Abstract][Full Text] [Related]
18. New insights to the potential mechanisms driving coronary flow reserve impairment in Cushing's syndrome: A pilot noninvasive study by transthoracic Doppler echocardiography. Tona F; Boscaro M; Barbot M; Maritan L; Famoso G; Dal Lin C; Montisci R; Fallo F; Iliceto S; Scaroni C Microvasc Res; 2020 Mar; 128():103940. PubMed ID: 31678361 [TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Bairey Merz CN; Handberg EM; Shufelt CL; Mehta PK; Minissian MB; Wei J; Thomson LE; Berman DS; Shaw LJ; Petersen JW; Brown GH; Anderson RD; Shuster JJ; Cook-Wiens G; Rogatko A; Pepine CJ Eur Heart J; 2016 May; 37(19):1504-13. PubMed ID: 26614823 [TBL] [Abstract][Full Text] [Related]
20. Inflammation, non-endothelial dependent coronary microvascular function and diastolic function-Are they linked? Suhrs HE; Schroder J; Bové KB; Mygind ND; Frestad D; Michelsen MM; Lange T; Gustafsson I; Kastrup J; Prescott E PLoS One; 2020; 15(7):e0236035. PubMed ID: 32673354 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]